Sabby Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Sabby Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-43,749	Closed	-$486K	–	216
2017 Q3	$486K	Sell	43,749 -143,751	-77%	-$1.35M	0.03%	102
2017 Q2	$1.73M	Sell	187,500 -102,587	-35%	-$855K	0.11%	78
2017 Q1	$2.48M	Sell	290,087 -67,719	-19%	-$617K	0.13%	77
2016 Q4	$3.83M	Buy	357,806 +259,756	+265%	+$3.14M	0.22%	65
2016 Q3	$1.06M	Buy	+98,050	New	+$797K	0.04%	179
2014 Q1	–	Sell	-68,100	Closed	-$1.33M	–	287
2013 Q4	$1.33M	Buy	+68,100	New	+$1.82M	0.09%	102

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Sabby Management's STML Position: Q4 2017 in Review

Sabby Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 43,749 shares — an estimated $486K sold.

Sabby Management first reported a position in STML in Q4 2013 and held it in 6 quarters. The position peaked at $3.83M in Q4 2016. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

Sabby Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Sabby Management sold 43,749 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $486K.
Sabby Management first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 6 quarters.
Sabby Management's Stemline Therapeutics, Inc. position peaked at $3.83M in Q4 2016.
80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.